LOXO-338 for Blood Cancers

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Eli Lilly and Company

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.

Eligibility Criteria

This trial is for US residents with advanced B-cell blood cancers who've had prior therapy, are in good physical condition (ECOG PS 0-1), and have a life expectancy of at least 12 weeks. They must be able to swallow pills, follow the study's outpatient requirements, and use effective birth control if necessary. Exclusions include certain lymphomas, CNS involvement, HIV positivity, recent major surgery or live vaccines, high-dose steroid use within a week of starting treatment, pregnancy or lactation.

Treatment Details

The trial is testing LOXO-338's safety and effectiveness in treating various types of advanced blood cancers over approximately three years. Some patients may also receive Pirtobrutinib as part of their treatment regimen. The goal is to determine how well these drugs work after standard treatments have been tried.

2Treatment groups

Experimental Treatment

Group I: LOXO-338 + Pirtobrutinib (Combination)Experimental Treatment2 Interventions

LOXO-338 administered orally in combination with pirtobrutinib

Group II: LOXO-338 (Monotherapy)Experimental Treatment1 Intervention

LOXO-338 administered orally.